Novo Nordisk A/S (NONOF)
USD 69.9
(6.72%)
USD 69.9
(6.72%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 83.68 Billion DKK | 50.71% |
| 2022 | 55.52 Billion DKK | 16.27% |
| 2021 | 47.75 Billion DKK | 13.33% |
| 2020 | 42.13 Billion DKK | 8.18% |
| 2019 | 38.95 Billion DKK | 0.84% |
| 2018 | 38.62 Billion DKK | 1.31% |
| 2017 | 38.13 Billion DKK | 0.54% |
| 2016 | 37.92 Billion DKK | 8.79% |
| 2015 | 34.86 Billion DKK | 31.64% |
| 2014 | 26.48 Billion DKK | 5.15% |
| 2013 | 25.18 Billion DKK | 17.51% |
| 2012 | 21.43 Billion DKK | 25.36% |
| 2011 | 17.09 Billion DKK | 18.7% |
| 2010 | 14.4 Billion DKK | 33.76% |
| 2009 | 10.76 Billion DKK | 11.4% |
| 2008 | 9.66 Billion DKK | 13.25% |
| 2007 | 8.53 Billion DKK | 32.27% |
| 2006 | 6.45 Billion DKK | 10.19% |
| 2005 | 5.85 Billion DKK | 16.0% |
| 2004 | 5.04 Billion DKK | 3.63% |
| 2003 | 4.87 Billion DKK | 19.1% |
| 2002 | 4.09 Billion DKK | 6.22% |
| 2001 | 3.85 Billion DKK | 24.71% |
| 2000 | 3.08 Billion DKK | 28.13% |
| 1999 | 2.41 Billion DKK | 0.06% |
| 1998 | 2.4 Billion DKK | 8.55% |
| 1997 | 2.21 Billion DKK | 23.11% |
| 1996 | 1.8 Billion DKK | 15.42% |
| 1995 | 1.56 Billion DKK | 9.1% |
| 1994 | 1.43 Billion DKK | 0.08% |
| 1993 | 1.43 Billion DKK | 12.39% |
| 1992 | 1.27 Billion DKK | 36.82% |
| 1991 | 930.19 Million DKK | 22.37% |
| 1990 | 760.12 Million DKK | 1.89% |
| 1989 | 745.98 Million DKK | 16.94% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 25.4 Billion DKK | 15.68% |
| 2024 Q2 | 20.05 Billion DKK | -21.08% |
| 2023 FY | 83.68 Billion DKK | 50.71% |
| 2023 Q3 | 22.47 Billion DKK | 15.7% |
| 2023 Q4 | 21.96 Billion DKK | -2.29% |
| 2023 Q1 | 19.81 Billion DKK | 45.78% |
| 2023 Q2 | 19.42 Billion DKK | -1.95% |
| 2022 Q1 | 14.21 Billion DKK | 30.46% |
| 2022 Q3 | 14.4 Billion DKK | 8.16% |
| 2022 FY | 55.52 Billion DKK | 16.27% |
| 2022 Q2 | 13.31 Billion DKK | -6.28% |
| 2022 Q4 | 13.59 Billion DKK | -5.64% |
| 2021 Q3 | 12.11 Billion DKK | -0.03% |
| 2021 Q4 | 10.89 Billion DKK | -10.12% |
| 2021 Q1 | 12.62 Billion DKK | 35.47% |
| 2021 Q2 | 12.12 Billion DKK | -3.96% |
| 2021 FY | 47.75 Billion DKK | 13.33% |
| 2020 Q4 | 9.31 Billion DKK | -9.52% |
| 2020 Q2 | 10.62 Billion DKK | -10.69% |
| 2020 Q1 | 11.89 Billion DKK | 36.48% |
| 2020 Q3 | 10.29 Billion DKK | -3.08% |
| 2020 FY | 42.13 Billion DKK | 8.18% |
| 2019 Q4 | 8.71 Billion DKK | -14.49% |
| 2019 Q1 | 10.44 Billion DKK | 22.93% |
| 2019 Q2 | 9.59 Billion DKK | -8.14% |
| 2019 Q3 | 10.19 Billion DKK | 6.24% |
| 2019 FY | 38.95 Billion DKK | 0.84% |
| 2018 Q2 | 10.34 Billion DKK | -3.79% |
| 2018 Q4 | 8.49 Billion DKK | -5.98% |
| 2018 Q1 | 10.75 Billion DKK | 30.27% |
| 2018 FY | 38.62 Billion DKK | 1.31% |
| 2018 Q3 | 9.03 Billion DKK | -12.63% |
| 2017 Q3 | 9.77 Billion DKK | -1.82% |
| 2017 FY | 38.13 Billion DKK | 0.54% |
| 2017 Q2 | 9.95 Billion DKK | -2.02% |
| 2017 Q4 | 8.25 Billion DKK | -15.53% |
| 2017 Q1 | 10.15 Billion DKK | 16.75% |
| 2016 Q3 | 9.8 Billion DKK | -1.66% |
| 2016 Q4 | 8.69 Billion DKK | -11.26% |
| 2016 Q1 | 9.45 Billion DKK | 14.5% |
| 2016 Q2 | 9.96 Billion DKK | 5.43% |
| 2016 FY | 37.92 Billion DKK | 8.79% |
| 2015 Q4 | 8.25 Billion DKK | -1.49% |
| 2015 Q3 | 8.38 Billion DKK | 0.48% |
| 2015 Q1 | 9.87 Billion DKK | 51.26% |
| 2015 Q2 | 8.34 Billion DKK | -15.52% |
| 2015 FY | 34.86 Billion DKK | 31.64% |
| 2014 Q3 | 6.5 Billion DKK | -7.06% |
| 2014 FY | 26.48 Billion DKK | 5.15% |
| 2014 Q1 | 6.45 Billion DKK | 6.69% |
| 2014 Q2 | 6.99 Billion DKK | 8.3% |
| 2014 Q4 | 6.52 Billion DKK | 0.45% |
| 2013 Q4 | 6.05 Billion DKK | -5.64% |
| 2013 FY | 25.18 Billion DKK | 17.51% |
| 2013 Q1 | 5.98 Billion DKK | 3.94% |
| 2013 Q2 | 6.73 Billion DKK | 12.57% |
| 2013 Q3 | 6.41 Billion DKK | -4.74% |
| 2012 Q1 | 4.66 Billion DKK | -0.53% |
| 2012 Q4 | 5.75 Billion DKK | 1.55% |
| 2012 FY | 21.43 Billion DKK | 25.36% |
| 2012 Q3 | 5.66 Billion DKK | 6.0% |
| 2012 Q2 | 5.34 Billion DKK | 14.62% |
| 2011 FY | 17.09 Billion DKK | 18.7% |
| 2011 Q2 | 4.13 Billion DKK | 1.5% |
| 2011 Q3 | 4.2 Billion DKK | 1.62% |
| 2011 Q4 | 4.68 Billion DKK | 11.62% |
| 2011 Q1 | 4.07 Billion DKK | 3.22% |
| 2010 Q1 | 3.32 Billion DKK | 43.09% |
| 2010 Q2 | 3.54 Billion DKK | 6.74% |
| 2010 Q3 | 3.58 Billion DKK | 1.04% |
| 2010 Q4 | 3.94 Billion DKK | 10.07% |
| 2010 FY | 14.4 Billion DKK | 33.76% |
| 2009 FY | 10.76 Billion DKK | 11.4% |
| 2009 Q3 | 2.75 Billion DKK | -7.89% |
| 2009 Q2 | 2.99 Billion DKK | 10.82% |
| 2009 Q1 | 2.69 Billion DKK | 14.44% |
| 2009 Q4 | 2.32 Billion DKK | -15.68% |
| 2008 Q4 | 2.35 Billion DKK | -11.46% |
| 2008 FY | 9.66 Billion DKK | 13.25% |
| 2008 Q2 | 2.47 Billion DKK | 13.66% |
| 2008 Q1 | 2.17 Billion DKK | 119.17% |
| 2008 Q3 | 2.66 Billion DKK | 7.67% |
| 2007 Q2 | 3.65 Billion DKK | 113.88% |
| 2007 Q4 | 993.1 Million DKK | -54.51% |
| 2007 FY | 8.53 Billion DKK | 32.27% |
| 2007 Q1 | 1.7 Billion DKK | -0.93% |
| 2007 Q3 | 2.18 Billion DKK | -40.23% |
| 2006 Q1 | 1.21 Billion DKK | 1.77% |
| 2006 FY | 6.45 Billion DKK | 10.19% |
| 2006 Q4 | 1.72 Billion DKK | -2.96% |
| 2006 Q2 | 1.74 Billion DKK | 43.92% |
| 2006 Q3 | 1.77 Billion DKK | 1.77% |
| 2005 Q4 | 1.19 Billion DKK | -31.88% |
| 2005 FY | 5.85 Billion DKK | 16.0% |
| 2005 Q3 | 1.74 Billion DKK | 4.11% |
| 2005 Q2 | 1.68 Billion DKK | 36.61% |
| 2005 Q1 | 1.22 Billion DKK | -14.6% |
| 2004 Q4 | 1.44 Billion DKK | 15.7% |
| 2004 FY | 5.04 Billion DKK | 3.63% |
| 2004 Q3 | 1.24 Billion DKK | 5.3% |
| 2004 Q1 | 1.06 Billion DKK | -21.5% |
| 2004 Q2 | 1.18 Billion DKK | 10.54% |
| 2003 Q1 | 1.08 Billion DKK | -6.66% |
| 2003 Q4 | 1.36 Billion DKK | 20.15% |
| 2003 Q3 | 1.13 Billion DKK | -11.32% |
| 2003 FY | 4.87 Billion DKK | 19.1% |
| 2003 Q2 | 1.27 Billion DKK | 17.56% |
| 2002 Q1 | 963.59 Million DKK | -5.43% |
| 2002 Q2 | 844.85 Million DKK | -12.32% |
| 2002 Q3 | 1 Billion DKK | 18.4% |
| 2002 Q4 | 1.16 Billion DKK | 16.48% |
| 2002 FY | 4.09 Billion DKK | 6.22% |
| 2001 Q1 | 1.02 Billion DKK | 64.17% |
| 2001 FY | 3.85 Billion DKK | 24.71% |
| 2001 Q4 | 1.01 Billion DKK | -3.23% |
| 2001 Q3 | 1.05 Billion DKK | 24.88% |
| 2001 Q2 | 843.16 Million DKK | -17.5% |
| 2000 Q2 | 931.99 Million DKK | 35.93% |
| 2000 Q3 | 1.74 Billion DKK | 87.28% |
| 2000 FY | 3.08 Billion DKK | 28.13% |
| 2000 Q4 | 622.51 Million DKK | -64.33% |
| 2000 Q1 | 685.62 Million DKK | 3.17% |
| 1999 Q2 | 634.12 Million DKK | 29.59% |
| 1999 Q4 | 664.56 Million DKK | 4.59% |
| 1999 FY | 2.41 Billion DKK | 0.06% |
| 1999 Q1 | 489.31 Million DKK | -18.35% |
| 1999 Q3 | 635.38 Million DKK | 0.2% |
| 1998 Q2 | 735.01 Million DKK | 25.67% |
| 1998 Q1 | 584.86 Million DKK | -9.81% |
| 1998 Q4 | 599.29 Million DKK | -0.64% |
| 1998 FY | 2.4 Billion DKK | 8.55% |
| 1998 Q3 | 603.15 Million DKK | -17.94% |
| 1997 Q4 | 648.5 Million DKK | 8.56% |
| 1997 Q2 | 551.28 Million DKK | 39.24% |
| 1997 Q1 | 395.92 Million DKK | -14.19% |
| 1997 FY | 2.21 Billion DKK | 23.11% |
| 1997 Q3 | 597.37 Million DKK | 8.36% |
| 1996 FY | 1.8 Billion DKK | 15.42% |
| 1996 Q4 | 461.41 Million DKK | -1.51% |
| 1996 Q3 | 468.51 Million DKK | 1.11% |
| 1996 Q2 | 463.37 Million DKK | 16.21% |
| 1996 Q1 | 398.72 Million DKK | 14.07% |
| 1995 FY | 1.56 Billion DKK | 9.1% |
| 1995 Q4 | 349.54 Million DKK | -20.88% |
| 1995 Q3 | 441.8 Million DKK | -1.33% |
| 1995 Q2 | 447.74 Million DKK | 45.79% |
| 1995 Q1 | 307.11 Million DKK | -37.95% |
| 1994 Q1 | 267.84 Million DKK | -36.75% |
| 1994 FY | 1.43 Billion DKK | 0.08% |
| 1994 Q4 | 494.96 Million DKK | 29.2% |
| 1994 Q3 | 383.1 Million DKK | 36.54% |
| 1994 Q2 | 280.57 Million DKK | 4.75% |
| 1993 Q4 | 423.5 Million DKK | 3.9% |
| 1993 Q2 | 293.66 Million DKK | 1.55% |
| 1993 Q3 | 407.61 Million DKK | 38.8% |
| 1993 Q1 | 289.18 Million DKK | -26.82% |
| 1993 FY | 1.43 Billion DKK | 12.39% |
| 1992 Q2 | 335.49 Million DKK | 3.64% |
| 1992 Q1 | 323.72 Million DKK | 0.0% |
| 1992 Q4 | 395.19 Million DKK | 73.02% |
| 1992 FY | 1.27 Billion DKK | 36.82% |
| 1992 Q3 | 228.41 Million DKK | -31.92% |
| 1991 Q4 | - DKK | 0.0% |
| 1991 Q1 | - DKK | 0.0% |
| 1991 Q2 | - DKK | 0.0% |
| 1991 Q3 | - DKK | 0.0% |
| 1991 FY | 930.19 Million DKK | 22.37% |
| 1990 Q3 | - DKK | 0.0% |
| 1990 Q4 | - DKK | 0.0% |
| 1990 Q2 | - DKK | 0.0% |
| 1990 FY | 760.12 Million DKK | 1.89% |
| 1990 Q1 | - DKK | 0.0% |
| 1989 Q3 | - DKK | 0.0% |
| 1989 Q1 | - DKK | 0.0% |
| 1989 Q2 | - DKK | 0.0% |
| 1989 Q4 | - DKK | 0.0% |
| 1989 FY | 745.98 Million DKK | 16.94% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | 1955309.367% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 111732.405% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 30608142.37% |
| SQZ Biotechnologies Company | -79.46 Million USD | 105409.322% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 2893308.878% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -157855.039% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -128380.337% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 4596733.504% |
| Marizyme, Inc. | -65.34 Million USD | 128159.603% |
| Genus plc | 7.9 Million USD | -1059178.481% |
| Pharming Group N.V. | -10.54 Million USD | 793454.19% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 3856790.02% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 2255564.211% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 946312.121% |
| ContraFect Corporation | -65.15 Million USD | 128540.747% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 4844394.063% |
| IMV Inc. | -36.48 Million USD | 229458.389% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 1038391.585% |
| ONE Bio Corp. | 8.67 Million USD | -964366.315% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 161987.72% |
| Mesoblast Limited | -87.95 Million USD | 95241.889% |
| MultiCell Technologies, Inc. | -380.07 USD | 22017786297.279% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 2241809.081% |
| Genscript Biotech Corporation | -95.47 Million USD | 87747.287% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 13232559.476% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 3514907.612% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 1272630.223% |
| Biomind Labs Inc. | -1.21 Million USD | 6891452.272% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 2698012.932% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 1058963.916% |
| Skye Bioscience, Inc. | -37.64 Million USD | 222396.401% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 4293189.287% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 768416.103% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 558780815.812% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 1712787.7% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 1198509.93% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 527355.146% |
| Accustem Sciences Inc. | -3.74 Million USD | 2233779.682% |
| EV Biologics, Inc. | -1.26 Million USD | 6604216.06% |
| Q BioMed Inc. | -2.05 Million USD | 4078034.09% |
| GB Sciences, Inc. | -1.36 Million USD | 6145683.718% |
| Alpha Cognition Inc. | -13.77 Million USD | 607706.411% |
| CSL Limited | 2.64 Billion USD | -3067.411% |
| Agentix Corp. | -1.37 Million USD | 6089630.647% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 140212.924% |
| Enzolytics Inc. | -2.17 Million USD | 3844356.24% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | -3.61 Million USD | 2318188.643% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 2638746.973% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 1438631.211% |
| argenx SE | -295.05 Million USD | 28462.023% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 133781.049% |
| HST Global, Inc. | -146.21 Thousand USD | 57234899.261% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -85390716.327% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 4768984.373% |
| Halberd Corporation | -79.67 Thousand USD | 105029217.928% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -1208389.624% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 2765442.59% |
| Zenith Capital Corp. | -10.59 Million USD | 789860.287% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 2106396.185% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 2018534.438% |
| AVAX Technologies, Inc. | -6.41 Million USD | 1304864.465% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 138455022.94% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 4173576.334% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 360050870.157% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 1754759.652% |
| Helix BioMedix, Inc. | -1.05 Million USD | 7924198.794% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 2191328.07% |
| Kadimastem Ltd | -3.3 Million USD | 2530276.29% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 986580.701% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 18959972.578% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 6266466.439% |
| LadRx Corporation | 400.44 Thousand USD | -20897505.901% |
| Cell Source, Inc. | -5.32 Million USD | 1572730.446% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 20141430.849% |
| Regen BioPharma, Inc. | 1.02 Million USD | -8175996.328% |
| Regen BioPharma, Inc. | 1.02 Million USD | -8175996.328% |
| Affymax, Inc. | -14.42 Million USD | 580265.003% |
| Mobile Lads Corp. | -2.26 Million USD | 3697501.838% |
| Itoco Inc. | -1.86 Million USD | 4477533.059% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 1883776.775% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 5014060.455% |
| International Stem Cell Corporation | -131 Thousand USD | 63880252.672% |
| CytoDyn Inc. | -49.84 Million USD | 167999.922% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 105883718.235% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 36682737.303% |
| Qrons Inc. | -789.34 Thousand USD | 10601647.862% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 8888089.642% |
| SYBLEU INC | -180.3 Thousand USD | 46412270.556% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 4008516.991% |
| Rebus Holdings, Inc. | -1.02 Million USD | 8204315.686% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 5188980.766% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 154191948.467% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 3307405.571% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 174178.466% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 3958614.664% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 10716503.27% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 2641608.838% |
| Neutra Corp. | -233.46 Thousand USD | 35844016.647% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 412514.371% |
| PureTech Health plc | -65.69 Million USD | 127477.201% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 393596.13% |
| IXICO plc | -1.17 Million USD | 7103920.034% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 843083.782% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 146583.336% |
| CSL Limited | 2.64 Billion USD | -3067.411% |
| Cellectis S.A. | -103.17 Million USD | 81208.73% |